Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGMNASDAQ:ETNBNYSE:MBXNASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMQilian International Holding Group$13.50-13.5%$12.11$5.26▼$17.17$1.31B1.3830,047 shs101,852 shsETNB89bio$10.41+8.2%$8.06$4.16▼$11.84$1.40B1.31.50 million shs3.93 million shsMBXMBX Biosciences$10.37-3.3%$10.38$4.81▼$27.50$346.61MN/A249,569 shs123,059 shsOCULOcular Therapeutix$8.73-2.5%$7.70$5.11▼$11.78$1.39B1.421.46 million shs1.10 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMQilian International Holding Group-13.52%+3.21%+16.88%+38.75%+1,349,999,900.00%ETNB89bio+8.21%+1.56%+26.95%+22.90%+10.04%MBXMBX Biosciences-3.26%-8.80%+1.97%+19.20%+1,036,999,900.00%OCULOcular Therapeutix-2.46%-3.22%+25.97%+13.08%+77.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/AETNB89bio2.4978 of 5 stars3.53.00.00.02.80.80.6MBXMBX Biosciences2.0167 of 5 stars3.50.00.00.00.03.30.6OCULOcular Therapeutix3.7943 of 5 stars3.41.00.04.13.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMQilian International Holding Group 0.00N/AN/AN/AETNB89bio 3.00Buy$26.43153.88% UpsideMBXMBX Biosciences 3.00Buy$37.50261.62% UpsideOCULOcular Therapeutix 2.88Moderate Buy$16.2586.14% UpsideCurrent Analyst Ratings BreakdownLatest MBX, ETNB, BGM, and OCUL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/29/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/10/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/6/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/30/2025ETNB89bioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/10/2025MBXMBX BiosciencesCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.004/10/2025MBXMBX BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.00 ➝ $44.004/10/2025MBXMBX BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$38.004/8/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMQilian International Holding Group$25.10M52.29N/AN/A$6.10 per share2.21ETNB89bioN/AN/AN/AN/A$5.75 per shareN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AN/AOCULOcular Therapeutix$59.65M23.32N/AN/A$0.79 per share11.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/AETNB89bio-$142.19M-$3.38N/AN/AN/AN/A-59.58%-52.21%8/4/2025 (Estimated)MBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/AOCULOcular Therapeutix-$80.74M-$1.15N/AN/AN/A-283.74%-45.18%-30.87%8/6/2025 (Estimated)Latest MBX, ETNB, BGM, and OCUL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025ETNB89bio-$0.50-$0.49+$0.01-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGMQilian International Holding GroupN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMQilian International Holding GroupN/A3.392.82ETNB89bio0.0911.6611.66MBXMBX BiosciencesN/AN/AN/AOCULOcular Therapeutix0.1913.0112.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMQilian International Holding GroupN/AETNB89bioN/AMBXMBX BiosciencesN/AOCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipBGMQilian International Holding Group58.66%ETNB89bio2.60%MBXMBX Biosciences52.19%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMQilian International Holding Group29897.22 million2.48 millionN/AETNB89bio40145.98 million103.15 millionOptionableMBXMBX Biosciences3633.42 millionN/AN/AOCULOcular Therapeutix230159.30 million151.71 millionOptionableMBX, ETNB, BGM, and OCUL HeadlinesRecent News About These CompaniesQ&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trialJune 11 at 8:10 PM | ophthalmologytimes.comCourier Capital LLC Boosts Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)June 10, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)June 8, 2025 | marketbeat.comAmeriprise Financial Inc. Purchases 40,700 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)June 3, 2025 | marketbeat.comOcular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMDJune 2, 2025 | ophthalmologytimes.comTwo Sigma Investments LP Buys 45,518 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)June 2, 2025 | marketbeat.comNuveen Asset Management LLC Has $3.54 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)June 2, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for OCUL Q1 Earnings?June 2, 2025 | marketbeat.comH.C. Wainwright maintains $15 target on Ocular Therapeutix stockMay 31, 2025 | investing.comVoloridge Investment Management LLC Has $286,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 31, 2025 | marketbeat.comMillennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 31, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DEMay 31, 2025 | marketbeat.comOcular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at HC WainwrightMay 30, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sanjay Nayak Sells 1,862 SharesMay 29, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Insider Peter Kaiser Sells 2,974 SharesMay 29, 2025 | marketbeat.comInsider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells 3,024 Shares of StockMay 29, 2025 | marketbeat.comPravin Dugel Sells 21,219 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockMay 29, 2025 | marketbeat.comDemystifying Ocular Therapeutix: Insights From 7 Analyst ReviewsMay 29, 2025 | benzinga.comOcular Therapeutix (NASDAQ:OCUL) Shares Down 4.8% - Here's What HappenedMay 29, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Trading Up 5.4% - Still a Buy?May 29, 2025 | marketbeat.comOcular Therapeutix chief scientific officer sells $21,712 in stockMay 29, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBX, ETNB, BGM, and OCUL Company DescriptionsQilian International Holding Group NASDAQ:BGM$13.50 -2.11 (-13.52%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$13.75 +0.25 (+1.85%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.89bio NASDAQ:ETNB$10.41 +0.79 (+8.21%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.85 -0.56 (-5.42%) As of 06/13/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.MBX Biosciences NYSE:MBX$10.37 -0.35 (-3.26%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$10.36 -0.01 (-0.09%) As of 06/13/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Ocular Therapeutix NASDAQ:OCUL$8.73 -0.22 (-2.46%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.72 -0.01 (-0.06%) As of 06/13/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
